Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rapid Advances In Cancer Treatment Fell Another Clinical Program

This article was originally published in Scrip

Executive Summary

The availability of new immuno-oncology treatments and heightening competition in lung cancer therapeutic development are behind a decision by GlaxoSmithKline and Five Prime Therapeutics, Inc. to discontinue development of their fibroblast growth factor (FGF) ligand trap in squamous non-small cell lung cancer. They will, however, continue an ongoing study in mesothelioma, and Five Prime said it would seek to take back rights from GSK for the indication should promising early data be confirmed by the full results of a Phase Ib study.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel